Patient Adherence

Determinants of virological failure among adults on first-line highly active antiretroviral therapy at public health facilities in Kombolcha town, Northeast, Ethiopia: a case-control study | BMJ | 7/27/2020

… viral load measurements within a 3-month interval, with adherence support between measurements) after at least 6 months of starting a new ART regimen. 6 Virological failure can occur for many reasons, such as patient adherence -related factors (missed clinic appointments, high pill burden and/or dosing frequency) and regimen-related factors (suboptimal pharmacokinetics, reduced efficacy due to prior exposure to suboptimal regimens). 11 Increasing and monitoring the capacity for …

Perceptions and Acceptability of Digital Interventions Among Tuberculosis Patients in Cambodia: Qualitative Study of Video-Based Directly Observed Therapy | 7/27/2020

Introduction Background Despite the development of effective drugs for treatment, tuberculosis (TB) remains one of the leading causes of death from an infectious disease worldwide [ 1 ]. One of the greatest challenges to TB control is patient adherence to treatment: the need to take drugs daily for 6 months often proves too burdensome, leading to late initiation (treatment delay), disruption (missed treatment), or early termination (treatment default). Nonadherence prolongs the period …

Follow Patient Adherence:    

Addressing Patient Adherence in Bipolar Disorder 1: Managing Comorbidities and Increasing Functional Ability | 7/25/2020

Addressing Patient Adherence in Bipolar Disorder 1: Managing Comorbidities and Increasing Functional Ability July 25, 2020 …

Insmed Receives Positive CHMP Opinion for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Non-CF Patients with Limited Treatment Options | PR Newswire | 7/24/2020

… Company’s estimates of the size of the potential markets for ARIKAYCE or brensocatib or in data the Company has used to identify physicians; expected rates of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates; the Company’s inability to create an effective direct sales and marketing infrastructure or to partner with third parties that offer such an infrastructure for distribution of ARIKAYCE; failure to obtain regulatory …

Strategies for effective patient services programs | 7/24/2020

… simply unknown because most manufacturers do not have adequate success criteria nor true understanding of the effectiveness of the programs. The struggle for effective patient services programs Implementing effective patient services programs to increase patient adherence is very challenging for many manufacturers. To start, many patient services initiatives often are siloed and uncoordinated. These programs typically are executed by multiple departments for multiple brands utilizing both internal teams and external …

Scoping review and bibliometric analysis of Big Data applications for Medication adherence: an explorative methodological study to enhance consistency in literature | 7/24/2020

… currently used to tackle medication adherence. We explore whether Big Data techniques are adopted to improve decision-making procedures regarding patients’ adherence, and the possible role of digital technologies in supporting interventions for improving patient adherence and avoiding waste or harm. Methods A scoping literature review and bibliometric analysis were used. Arksey and O’Malley’s framework was adopted to scope the review process, and a bibliometric analysis was applied to observe …

How Real World Evidence Analytics Can Accelerate COVID-19 Drug Discovery and Vaccine Trials | Quantzig | Business Wire | 7/23/2020

… of the world’s leading analytics solutions provider, committed to offering cutting-edge analytics solutions to help organizations institutionalize data-driven decision making. Quantzig’s real world evidence analytics solutions provide comprehensive insights on treatment pathways, patient adherence , disease progression, pricing levels and market access, drug safety, and patient engagement. All of which play a pivotal role in enhancing drug discovery and driving healthcare outcomes. Connect with our experts to gain limited …

IntegriChain Summer Release Advances Patient Data Insights and Actionability of Industry-Leading ICyte Access Platform | PR Newswire | 7/22/2020

… in data stewardship and data quality that we deliver to manufacturers with this release. Our solutions uniquely allow manufacturers to identify and resolve patient access barriers and friction points in specialty pharmacies, hubs, and patient adherence services to help more patients start and stay on therapy. We thank our early visionary customers that partnered with us and played an integral role in our ability to mature these patient access solutions …

Effects of Tart Cherry Powder on Serum Uric Acid in Hyperuricemia Rat Model | 7/22/2020

… their metabolites, which consequently prolongs their plasma half-lives and increases the risk of serious adverse events, such as Stevens–Johnson syndrome and toxic epidermal necrolysis induced by allopurinol [ 15 ]. It was estimated that patient adherence to prescribed urate-lowering therapies ranges from 20% to 70%. Besides, a survey showed that patients had a high degree of interest in nonpharmacological therapies for gout [ 16 ]. Physicians advise patients to take fruits …

Sterling Reference Laboratories Reaches Final Agreement With U.S. Government | PR Newswire | 7/21/2020

… pharmacies, which specialize in the complex management and dispensing of controlled substances. Cordant’s testing protocols and digital case-management tools help clients become more efficient and effective in using drug testing programs to monitor patient adherence , reduce risk and improve patient outcomes. Media Contact: Tiffany Tuetken [email protected] 303-570-4585 SOURCE Cordant Health Solutions …

Wearable Drug Delivery Provider Sorrel Medical Partners with Leading Global Pharmaceutical Manufacturer | PR Newswire | 7/21/2020

… PhD, CEO of Sorrel Medical. “Combining our platform approach to development with our partner’s extensive expertise in pharmaceutical formulation and market penetration, we can provide solutions that enhance the self-administration experience while encouraging patient adherence to treatments.” About Sorrel Medical: Sorrel Medical, an Eitan Group company, is a medical device company focused on the development and commercial manufacturing of platform-based, pre-filled and pre-loaded wearable injectors for …

Top Three Predictions for the Biosimilar Industry in the MENA Region Post-COVID-19 | 7/16/2020

… became explicit that there would be a decline of about 6% to 10% from the original estimate. This decline is attributed to the international supply chain disruptions, nation-wide lockdowns, overwhelmed healthcare infrastructure, poor patient adherence for injectable products and delay in the approvals and commercialization of new biosimilars in the region. This decline will not cause long-term disruptions as patients requiring biological products have chronic conditions and their …

Elucid’s Dashboard Gives Pharma Real Time Patient Adherence Data during Clinical Trials | 7/15/2020

TOPICS: ePharma mHealth Pharma July 15, 2020 Understanding and monitoring meditation adherence during clinical trials is a problematic process. Researchers need to know that trial participants have administered the correct dosage at the appropriate times in order to fully document the impact of a particular medication. Elucid’s Pill Connect dispensing system, is one solution that is looking to provides CROs and pharma with the ability to show adherence across the …

EVERSANA™ adds powerful predictive analytics platform with HVH Precision Analytics acquisition | PR Newswire | 7/15/2020

… are now powered by a military grade analytics platform which will optimize every corner of our operation, ranging from our strategies to ensure long-term market access and revenue management to our services improving patient adherence ,” said Jim Lang , CEO, EVERSANA. HVH Precision Analytics is widely recognized as a leader in the space and in 2018 was named Pharma Tech Outlook magazine’s Company of the Year for its work in …

Anti-CD20 Monoclonal Antibodies (mABs) Market Detailed Analysis and Forecast by 2028 | BioSpace | 7/14/2020

There are various drugs available in the market for the treatment of diseases like cancer, autoimmune disorders, and various other neurological disorders. However, majority of these drugs have side-effects associated with them which are resulting low patient adherence . Owing to these side-effects and various research and developments in the field of targeted therapies, like anti-CD20 mABs, have increased over the period of time. As a result of …

Diabetes Drugs Market: Type 2 Diabetes with Vast Unmet Need in Patients Bellwether for Market Growth Globally | BioSpace | 7/14/2020

Growing discovery of new medication classes with the objective of stopping the steep rise in worldwide prevalence has invigorated the growth of the diabetes drugs market . Growing body of research in pharmacological therapies, with focus on efficacy, safety, and patient adherence , has expanded market avenues for antidiabetic drugs. Growing classes of drugs to treat type 2 diabetes mellitus has been a key driver and accelerator for expansion of the diabetes …

First Fill Buy Downs: Maximizing Return in the Face of Prior Authorization – PM360 | 7/14/2020

… ill-advised to assume this is a change that will happen any time soon, if ever. 1 In light of this, what can brands do to grow their profitability and market share, while supporting patient adherence and maintaining their first-choice status among HCPs? Is it wise to focus solely on the fight against expanding PA requirements, or can there be another way to combat the issue simultaneously? Electronic Prior …

Two Key Questions About Adherence/Compliance in 2020 – PM360 | 7/14/2020

PM360 asked experts who know how to improve medication adherence about the new challenges that COVID-19 will bring and what other barriers companies should pay particular attention to. More precisely, we asked them: How will the COVID-19 pandemic impact patient adherence ? How can companies address short-term effects such as an inability to see their doctor, pick up prescriptions, or pay for medication? And what longer term impact …

Automatic Recognition, Segmentation, and Sex Assignment of Nocturnal Asthmatic Coughs and Cough Epochs in Smartphone Audio Recordings: Observational Field Study | 7/14/2020

… symptoms, and less use of rescue medication [ 4 - 6 ]. The implementation of these programs, however, is low in clinical practice, with only 27% of adults with asthma receiving an asthma action plan [ 7 ]. Also, patient adherence to written action plans is poor and declines over time [ 8 ], and due to the reliance on subjective information in action plans, patients may perceive their symptoms poorly, and thus, underestimate the severity of …

How telehealth holds the key to patient activation | Healthcare IT News | 7/14/2020

Activated and engaged patients are more likely to follow their treatment plans – and this could be a major benefit for healthcare providers as the use of telehealth tools continues to rise in the wake of the pandemic. By: July 14, 2020 09:02 AM As health systems have adjusted their workflows to deal with the coronavirus pandemic, they have discovered increasing value in telehealth solutions that will continue to offer benefits …

Self-Insured Employers, Plan Sponsors Discover Value of Specialty PBM & Medical Infusion Carve-Outs: Largest TPAs, SIIA Regulatory Expert Present Episode 2, AscellaHealth Educational Webinars | Business & Finance | manchestertimes.com | Business Wire | 7/14/2020

… therapies; and 16 were to treat different cancers. Currently, only 7% of rare diseases have treatments. “AscellaHealth’s specialty and medical Rx management services are designed to reduce costs, increase specialty drug availability and promote patient adherence through appropriate disease therapy management and enhanced patient outcomes,” adds Belazi. “In addition to its full-service PBM capabilities, AscellaHealth provides full and custom PBM services to commercial, Medicare and Medicaid market segments with …

A cohort study of medication adherence among patients with chronic obstructive pulmonary disease in Egypt | 7/14/2020

… and burden of COPD in low- and middle-income countries, there are limited data related to COPD treatment adherence in these countries, including the potential role of physicians, pharmacists, and/or social support in patient adherence to COPD therapy. The goal of the current study was to identify factors associated with treatment adherence, especially the role of the physician, pharmacist, and social support, in making the decision to discontinue inhaled …

Assessment of Parkinsonian gait in older adults with dementia via human pose tracking in video data | 7/14/2020

… Studies on quantitative gait analysis in patients with PD have primarily relied on wearable sensors for data collection [ 6 , 7 ]. However, wearables require physical contact with the patient and suffer from significant challenges with patient adherence in non-clinical settings [ 8 ]. Additionally, because locomotion requires coordinated movement of the entire body, multiple sensors are often required to accurately quantify gait features [ 9 ]. In contrast, computer vision systems are well-suited …

Opinion: To thrive, Black and Latinx physicians need their communities | STAT | 7/9/2020

… you.” “You listen to me.” “I’m so proud of you.” A growing number of studies have suggested that a shared racial/ethnic background between physician and patient improves rapport, enhances shared decision-making, improves patient adherence to treatment, and influences health . To put it simply, Black and Latinx doctors are good for Black and Latinx patients. Related: ‘It just weighs on your psyche’: Black Americans on mental health, trauma, and …

ChronWell Launches Remote Physiologic Monitoring (RPM) Services for Gastrointestinal Physicians and Patients | PRWeb | 7/9/2020

… 09, 2020 ChronWell, a technology-enabled remote care management company, today announced the addition of its Remote Physiologic Monitoring (RPM) services. The goal of the new program is to closely monitor progress and improve patient adherence to treatment plans, reduce complications and help practices deliver better care while optimizing costs. ChronWell RPM services will initially focus on patients with IBS (irritable bowel syndrome) and IBD (inflammatory bowel disease). Through digital …

Department of Health and Human Services

Sterling Reference Laboratories Reaches Final Agreement With U.S. Government | PR Newswire | 7/21/2020

… patients. Cordant also entered into a Corporate Integrity Agreement with the Office of the Inspector General for the United States Department of Health and Human Services, under which the Company will strengthen specific corporate compliance … efficient and effective in using drug testing programs to monitor patient adherence, reduce risk and improve patient outcomes. Media Contact: Tiffany Tuetken [email protected] 303-570-4585 SOURCE Cordant Health Solutions …

Telehealth

How telehealth holds the key to patient activation | Healthcare IT News | 7/14/2020

… likely to follow their treatment plans – and this could be a major benefit for healthcare providers as the use of telehealth tools continues to rise in the wake of the pandemic. By: July 14, 2020 … and enable convenient access to care. Why patient activation matters Patient adherence to a long-term treatment plan can sometimes be quite low. This might be due to simple things such as not taking the …

Food and Drug Administration

New NTM Treatment Guidelines Recommend Insmed’s ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of Patients with Refractory MAC Lung Disease | PR Newswire | 7/7/2020

… therapy approved in the United States for the treatment of refractory NTM lung disease caused by MAC. ARIKAYCE received U.S. Food and Drug Administration (FDA) accelerated approval based on results of the Phase 3 CONVERT … rates of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates; the Company’s inability to create an effective direct sales and marketing infrastructure or to partner with third parties that offer …

COVID-19

Cordant Offers Virtual Drug Testing to Provide Drug Courts and Other Government Agencies the Ability to Maintain Accountability for Participants During COVID-19 | PR Newswire | 6/30/2020

… Offers Virtual Drug Testing to Provide Drug Courts and Other Government Agencies the Ability to Maintain Accountability for Participants During COVID-19 Press Release - updated: Jun 30, 2020 08:00 MDT DENVER, June 30, 2020 (Newswire.com … efficient and effective in using drug testing programs to monitor patient adherence, reduce risk and improve patient outcomes. Media Contact …

Digital Health

Digital pill developer Proteus files for bankruptcy | FierceBiotech | 6/17/2020

Proteus Digital Health—makers of an ingestible sensor embedded within a pill to track medication usage—has filed for bankruptcy, after failing to raise funding in part due to the COVID-19 pandemic. The company’s … taken—aimed to tackle Big Pharma’s long-standing troubles with patient adherence. RELATED: Proteus’ digital pill tracker shows success in TB drug adherence It was first approved as a medication by the FDA in 2017 …

ACOs

Wanda Health’s Rapid Deployment Telehealth for COVID-19 Screening and Care Management Selected by FL and WA Providers | PRWeb | 4/9/2020

… diagnosed with the virus.” The first provider is PCP1st, a Florida based experts in delivering customized care management for CINs, ACOs, MSOs. The second provider is Washington based Lake Chelan Community Hospital and Clinics providing … experiencing reductions in unplanned rehospitalizations and emergency department visits, increased patient adherence, added revenue and reduced costs of operations. About PCP1st ( https://www.pcp1st.com/ ) Providing healthcare solutions for CINs, ACOs, MSOs and individual healthcare provider offices …

Readmissions

Care Dimensions Improves Quality of Life for Hospice Patients Using Telehealth | PR Newswire | 12/4/2019

patient adherence rates of nearly 90% and has been essential to their reduction of hospital readmissions and ED visits.” In the coming months, Care Dimensions’ clinical team will further expand their use of virtual visits, scheduling virtual visits following patient enrollment and installation to answer questions and ensure patient and caregiver comfort with the telehealth program. “The use of telehealth has enabled our team to personalize care to each patients …

Hospital Readmissions

Care Dimensions Improves Quality of Life for Hospice Patients Using Telehealth | PR Newswire | 12/4/2019

patient adherence rates of nearly 90% and has been essential to their reduction of hospital readmissions and ED visits.” In the coming months, Care Dimensions’ clinical team will further expand their use of virtual visits, scheduling virtual visits following patient enrollment and installation to answer questions and ensure patient and caregiver comfort with the telehealth program. “The use of telehealth has enabled our team to personalize care to each patients …

EMR

Care Dimensions Improves Quality of Life for Hospice Patients Using Telehealth | PR Newswire | 12/4/2019

… care team, tracking the intervention, contacting the patient’s primary case manager, and ensuring data is transmitted to the Care Dimensions’ EMR to inform all providers on the interdisciplinary team. Pain management, education, and engagement are … Their commitment to patient and caregiver engagement has resulted in patient adherence rates of nearly 90% and has been essential to their reduction of hospital readmissions and ED visits.” In the coming months, Care Dimensions …

Medication Management

Care Dimensions Improves Quality of Life for Hospice Patients Using Telehealth | PR Newswire | 12/4/2019

… CHF, are evaluated for the telehealth program. Patients with a history of frequent ED visits or requiring focused weight and medication management are enrolled in the telehealth program to receive the additional support telehealth provides … Their commitment to patient and caregiver engagement has resulted in patient adherence rates of nearly 90% and has been essential to their reduction of hospital readmissions and ED visits.” In the coming months, Care Dimensions …

Remote Monitoring

Care Dimensions Improves Quality of Life for Hospice Patients Using Telehealth | PR Newswire | 12/4/2019

… being. In Massachusetts , Care Dimensions is one of the first healthcare providers to offer the advanced support of telehealth and remote monitoring to hospice and palliative patients and their families. All patients referred to Care … Their commitment to patient and caregiver engagement has resulted in patient adherence rates of nearly 90% and has been essential to their reduction of hospital readmissions and ED visits.” In the coming months, Care Dimensions …

Pain Management

Care Dimensions Improves Quality of Life for Hospice Patients Using Telehealth | PR Newswire | 12/4/2019

… case manager, and ensuring data is transmitted to the Care Dimensions’ EMR to inform all providers on the interdisciplinary team. Pain management, education, and engagement are fundamental aspects of hospice and palliative care, not only … Their commitment to patient and caregiver engagement has resulted in patient adherence rates of nearly 90% and has been essential to their reduction of hospital readmissions and ED visits.” In the coming months, Care Dimensions …

Medication Adherence

Study: AdhereTech’s smart pill bottle intervention improves adherence without major additional expense | MobiHealthNews | 12/3/2019

… from each arm completed their treatment cycle and were included for six-month analysis. Among these, researchers reported that median medication adherence was higher among those provided the smart pill bottle intervention (100% versus 87.4 … published peer review study that extends beyond the endpoints of patient adherence and experience. “The really neat stuff is in addition to adherence, [the upcoming study] addresses other health outcomes for patients. What I mean …

Electronic Health Records

Financial Contrast: OptimizeRx (NASDAQ:OPRX) and NetEase (NASDAQ:NTES) | 12/2/2019

patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information; and network consists of electronic health records platforms, which provide the ambulatory patient market with access to their workflow at the point-of-care. Its products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient …

Clinical Messaging

Financial Contrast: OptimizeRx (NASDAQ:OPRX) and NetEase (NASDAQ:NTES) | 12/2/2019

… Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers. The company’s cloud-based solutions support patient adherence to medications by providing real-time access to financial assistance, prior authorization, education … well as for a network of pharmacies; and Brand and Clinical Messaging that includes various brand awareness and clinical messaging services consisting of brand awareness messages, reminder ads, clinical messages, and unbranded messages targeted by …

Molecular Diagnostics

Epigenomics AG Reports on New Micro-Simulation Study Results Published in Cancer Medicine Indicating That Epi proColon® Provides Clinically Meaningful Reductions in Incidence and Mortality of Colorectal Cancer | BioSpace | 12/2/2019

… for CRC offers the highest sensitivity of all available screening strategies, the results of this micro-simulation model demonstrate that patient adherence and prescribed screening intervals heavily influence the long-term clinical effectiveness for all … laboratory. Epi proColon is recipient of the 2019 Excellence in Molecular Diagnostics by Corporate LiveWire’s Innovation and Excellence Awards. For more information on Epi proColon, visit www.epiprocolon.com . About Epigenomics Epigenomics is a molecular diagnostics company …

Medicare

Exact Sciences to participate in December investor conference | PR Newswire | 11/26/2019

… looking statements include, among others, statements we make regarding expected future operating results, anticipated results of our sales, marketing and patient adherence efforts, expectations concerning payer reimbursement, the anticipated results of our product development efforts … without limitation as a result of the Protecting Access to Medicare Act of 2014; recommendations, guidelines and quality metrics issued by various organizations such as the U.S. Preventive Services Task Force, the American Cancer Society …

Diagnostic Tests

Exact Sciences to participate in December investor conference | PR Newswire | 11/26/2019

… investor relations section of Exact Sciences’ website at www.exactsciences.com . About Exact Sciences Corp. A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing … future operating results, anticipated results of our sales, marketing and patient adherence efforts, expectations concerning payer reimbursement, the anticipated results of our product development efforts and the anticipated benefits of our acquisition of Genomic Health …

National Committee for Quality Assurance

Exact Sciences to participate in December investor conference | PR Newswire | 11/26/2019

… looking statements include, among others, statements we make regarding expected future operating results, anticipated results of our sales, marketing and patient adherence efforts, expectations concerning payer reimbursement, the anticipated results of our product development efforts … Preventive Services Task Force, the American Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services and assess potential …

Patient Satisfaction

Mine Your EMR for Data and Improve Patient Safety | FierceHealthcare | 11/25/2019

… the risks of anticoagulation therapy. Anticoagulation therapy involves complex dosing, and it’s often further complicated by insufficient monitoring and inconsistent patient adherence. Tracking the patient education you give these patients will help you improve safety … or specialty to identify training opportunities. You can illustrate whether patient satisfaction scores went up when patient education was used more often. You can even compare how the timing of the education (where in the …

Patient Monitoring

The global autotransfusion devices market at a CAGR of almost 6% during the forecast period | PR Newswire | 11/25/2019

patient monitoring much simpler and cost-effective and contributes to higher patient adherence to health monitoring. Thus, all these factors have the potential to accelerate the growth of the global healthcare equipment market, including the global autotransfusion devices market. Moreover, several companies focus on the development of technological platforms that are integrated with autotransfusion systems to provide blood products to patients during surgical procedures This development is expected to have …

Consumer Engagement

Primary Care System Falling Short for Vulnerable Patients | Patient Engagement HIT | 11/25/2019

… calling for a more personal, patient-centered experience, according to a series of focus groups conducted by the Center for Consumer Engagement in Health Innovation. The nine focus groups included individuals with complex social and … and care navigators could help drive care coordination and ensure patient adherence to care and social services plans. Third, and as noted above, focus group participants were interested in having discussions with their providers that …

Patient Safety

Mine Your EMR for Data and Improve Patient Safety | FierceHealthcare | 11/25/2019

… business of helping patients, not running numbers, right?—but what if I told you this information could help you improve patient safety and outcomes? I recently teamed up with Vicki Maisonneuve, director of the Nursing … and it’s often further complicated by insufficient monitoring and inconsistent patient adherence. Tracking the patient education you give these patients will help you improve safety 1 . 2. Decide what (and who) to track. Now you …

Behavioral Healthcare

Primary Care System Falling Short for Vulnerable Patients | Patient Engagement HIT | 11/25/2019

… they need to access. On the provider side, case workers and care navigators could help drive care coordination and ensure patient adherence to care and social services plans. Third, and as noted above, focus group … or the idea that they could receive medical, mental, and behavioral healthcare all under one roof. Separate studies suggest primary care and mental healthcare integration improves health outcomes. Finally, patients are looking for a primary …

Population Health

Primary Care System Falling Short for Vulnerable Patients | Patient Engagement HIT | 11/25/2019

… they need to access. On the provider side, case workers and care navigators could help drive care coordination and ensure patient adherence to care and social services plans. Third, and as noted above, focus group … the medical industry, meaning it is still possible to drive population health efforts. “Marginalized consumers, facing many barriers and often complex needs, are not being well-served by the present system,” the researchers concluded. “Despite …

Quantzig

How Real World Evidence Analytics Can Accelerate COVID-19 Drug Discovery and Vaccine Trials | Quantzig | Business Wire | 7/23/2020

LONDON–(BUSINESS WIRE)–Jul 23, 2020– Quantzig, one of the world’s leading analytics solutions provider, committed to offering cutting-edge analytics solutions to help organizations institutionalize data-driven decision making. Quantzig’s real world evidence analytics solutions provide comprehensive insights on treatment pathways, patient adherence, disease progression, pricing levels and market access, drug safety, and patient engagement. All of which play a pivotal role in enhancing drug discovery and driving healthcare …

Propeller Health

Propeller gets green light to bundle its digital health tools with inhalers - MedCity News | 7/8/2020

Propeller Health received approval from the European Commission to co-package its digital health platform with Novartis’ Enerzair Breezhaler inhaler. Photo credit: Propeller Health European regulators gave Novartis and Propeller Health the green light to co-package their products, opening the door for digital health products and medications to be prescribed together for the first time. Propeller Health makes sensors that attach to inhalers. The software monitors patient adherence and …

Novartis

Propeller gets green light to bundle its digital health tools with inhalers - MedCity News | 7/8/2020

Propeller Health received approval from the European Commission to co-package its digital health platform with Novartis’ Enerzair Breezhaler inhaler. Photo credit: Propeller Health European regulators gave Novartis and Propeller Health the green light to co-package their products, opening the door for digital health products and medications to be prescribed together for the first time. Propeller Health makes sensors that attach to inhalers. The software monitors patient adherence and …

Oncotype

Exact Sciences schedules annual meeting, second quarter 2020 earnings call | PR Newswire | 7/8/2020

… relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier. Building on the success of Cologuard and Oncotype DX, Exact Sciences is investing in its product pipeline to take on some of … future operating results, anticipated results of our sales, marketing and patient adherence efforts, expectations concerning payer reimbursement, and the anticipated results of our product development efforts. Forward-looking statements are neither historical facts nor assurances …

Exact Sciences

Exact Sciences schedules annual meeting, second quarter 2020 earnings call | PR Newswire | 7/8/2020

Exact Sciences schedules annual meeting, second quarter 2020 earnings call News provided by Jul 08, 2020, 06:00 ET Share this article MADISON, Wis. , July 8, 2020 /PRNewswire/ – Exact Sciences Corp. (Nasdaq: EXAS ) today announced that … future operating results, anticipated results of our sales, marketing and patient adherence efforts, expectations concerning payer reimbursement, and the anticipated results of our product development efforts. Forward-looking statements are neither historical facts nor assurances …

AstraZeneca

Association Of Community Cancer Centers Releases Preliminary Findings From Survey On Advanced Non-Small Cell Lung Cancer Care | PR Newswire | 6/18/2020

… care delivery and outcomes for advanced non-small cell lung cancer (NSCLC) patients. The initiative was developed with support from AstraZeneca and in partnership with the American College of Chest Physicians (CHEST), the International Association … limited access to diagnostic procedures, poor handling of biopsy tissue, patient adherence to appointment schedules, and lack of communication among the multidisciplinary team. “We have a paradox in lung cancer care. There are incredible advances …

Genentech

Bristol Myers Squibb’s Zeposia and Janssen’s Ponesimod Could Be Early-Line Winners, While Biogen’s Vumerity Appears Relegated to Tolerability Switches Within the Fumarate Class | PR Newswire | 6/16/2020

… pandemic has had a high impact on their practice. Indeed, among the subset of neurologists who report decreased use of Genentech’s Ocrevus over the past three months, nearly all cite COVID-19 as a strong … of patient convenience may be overshadowed by potential shortcomings on patient adherence. Spherix will continue to track neurologists’ pre-market perceptions of ofatumumab as the anticipated FDA decision nears. About RealTime Dynamix™ RealTime Dynamix™: Multiple …

IQVIA

AllazoHealth names pharmaceutical industry analytics expert Mark Degatano to advisory board | PRWeb | 4/9/2020

… joining the company’s Advisory Board. “The AllazoHealth approach of using artificial intelligence effectively addresses an important, long-standing problem in patient adherence and engagement,” said Mr. Degatano. NEW YORK (PRWEB) April 09, 2020 AllazoHealth, a … at numerous data and service providers, including Symphony Health, Prognos, IQVIA, and Aptus Health. “The AllazoHealth approach of using artificial intelligence effectively addresses an important, long-standing problem in patient adherence and engagement,” said Mr …

AllazoHealth

AllazoHealth names pharmaceutical industry analytics expert Mark Degatano to advisory board | PRWeb | 4/9/2020

AllazoHealth names pharmaceutical industry analytics expert Mark Degatano to advisory board Share Article AllazoHealth, a company that uses artificial intelligence to help pharmaceuticals, payers, and pharmacies improve medication adherence and quality outcomes, announced today that pharmaceutical industry veteran Mark Degatano will be joining the company’s Advisory Board. “The AllazoHealth approach of using artificial intelligence effectively addresses an important, long-standing problem in patient adherence and engagement,” said Mr. Degatano. NEW …

Medtronic

ACC: Medtronic’s renal denervation study returns, showing drops in stubbornly high blood pressure | FierceBiotech | 3/29/2020

Medtronic is back with new data finally demonstrating the effectiveness of its catheter-based ablation procedure aimed at the kidneys to help lower high blood pressure where multiple medications have failed. Known as renal denervation … offers an effective alternative approach to traditional medications that require patient adherence for reducing blood pressure,” said study lead author Michael Böhm of the Saarland University Medical Center in Hamburg, Germany. The 24-hour wearable …

OptimizeRx

Financial Contrast: OptimizeRx (NASDAQ:OPRX) and NetEase (NASDAQ:NTES) | 12/2/2019

20.90% Insider and Institutional Ownership 60.6% of OptimizeRx shares are held by institutional investors. Comparatively, 48.2% of NetEase shares are held by institutional investors. 8.4% of OptimizeRx shares are held by company insiders. Comparatively, 54.7 … communicate with healthcare providers. The company’s cloud-based solutions support patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information; and network consists of electronic health …

Pfizer

Exact Sciences to participate in December investor conference | PR Newswire | 11/26/2019

… looking statements include, among others, statements we make regarding expected future operating results, anticipated results of our sales, marketing and patient adherence efforts, expectations concerning payer reimbursement, the anticipated results of our product development efforts … utilize strategic partnerships, such as through our Promotion Agreement with Pfizer, Inc., and acquisitions; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations …

Genomic Health

Exact Sciences to participate in December investor conference | PR Newswire | 11/26/2019

patient adherence efforts, expectations concerning payer reimbursement, the anticipated results of our product development efforts and the anticipated benefits of our acquisition of Genomic Health, including estimated synergies and other financial impacts. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and …

Boehringer Ingelheim

Optimising Clinical Outcomes in Asthma and Chronic Obstructive Pulmonary Disease: Focus on Inhaler Satisfaction and Patient Adherence | 11/14/2019

… Spain University of Florence, Florence, Italy Locum General Practitioner, London, UK Disclosure: Prof Bateman reports personal fees from AstraZeneca, ALK, Boehringer Ingelheim, Cipla, ICON, Menarini, Novartis, Orion, Sanofi/Regeneron, and Vectura. He has also received … there are other factors that should be considered to maximise patient adherence, such as the technical characteristics of inhaled therapy. 1 Two systematic reviews of inhaler device use have shown, rather surprisingly, that a substantial …

Merck

Optimising Clinical Outcomes in Asthma and Chronic Obstructive Pulmonary Disease: Focus on Inhaler Satisfaction and Patient Adherence | 11/14/2019

… Cipla, ICON, Menarini, Novartis, Orion, Sanofi/Regeneron, and Vectura. He has also received grants to institution from AstraZeneca, Boehringer Ingelheim, Merck, Takeda, GSK, Hoffmann le Roche, Actelion, Chiesi, Sanofi-Aventis, Cephalon, Teva, and Novartis. Prof … there are other factors that should be considered to maximise patient adherence, such as the technical characteristics of inhaled therapy. 1 Two systematic reviews of inhaler device use have shown, rather surprisingly, that a substantial …

GlaxoSmithKline

Optimising Clinical Outcomes in Asthma and Chronic Obstructive Pulmonary Disease: Focus on Inhaler Satisfaction and Patient Adherence | 11/14/2019

… Cephalon, Teva, and Novartis. Prof Kuna reports receiving honoraria from Adamed, Allergopharma, Almirall, AstraZeneca, Boehringer Ingelheim, Celon Pharma, Chiesi, FAES, GlaxoSmithKline, Hal, Meda, Menarini, Merck Sharp & Dohme, Novartis, Orion, Pfizer, Polfarmex, Polpharma, Stallergenes Greer, Teva … there are other factors that should be considered to maximise patient adherence, such as the technical characteristics of inhaled therapy. 1 Two systematic reviews of inhaler device use have shown, rather surprisingly, that a substantial …

GSK

Optimising Clinical Outcomes in Asthma and Chronic Obstructive Pulmonary Disease: Focus on Inhaler Satisfaction and Patient Adherence | 11/14/2019

… Menarini, Novartis, Orion, Sanofi/Regeneron, and Vectura. He has also received grants to institution from AstraZeneca, Boehringer Ingelheim, Merck, Takeda, GSK, Hoffmann le Roche, Actelion, Chiesi, Sanofi-Aventis, Cephalon, Teva, and Novartis. Prof Kuna reports … there are other factors that should be considered to maximise patient adherence, such as the technical characteristics of inhaled therapy. 1 Two systematic reviews of inhaler device use have shown, rather surprisingly, that a substantial …

Sandoz

Optimising Clinical Outcomes in Asthma and Chronic Obstructive Pulmonary Disease: Focus on Inhaler Satisfaction and Patient Adherence | 11/14/2019

… reports speaker fees, travel grants, and advisory board fees from AstraZeneca, Bayer, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Menarini, Novartis, Orion, Pfizer, Sandoz, and Teva. Prof Lavorini has received research grants and honoraria from AstraZeneca, Boehringer Ingelheim … there are other factors that should be considered to maximise patient adherence, such as the technical characteristics of inhaled therapy. 1 Two systematic reviews of inhaler device use have shown, rather surprisingly, that a substantial …

Allscripts

OptimizeRx Reports Third Quarter 2019 Results | Globe Newswire | 11/5/2019

patient adherence to medications and better healthcare outcomes with real-time access to financial assistance, prior authorization, education and critical clinical information. OptimizeRx provides more than half of the ambulatory patient market with access to these benefits through leading EHR platforms like Allscripts, Amazing Charts and Quest, and directly via its mobile communications platform and digital therapeutics SaaS platform. For more information, follow the company on Twitter , LinkedIn or visit …

Allergan

Evaluating surface-based sustained delivery platforms for glaucoma | 11/4/2019

… hese days a variety of surface-based systems for delivering glaucoma medication to the eye are being explored to overcome patient adherence problems, peak and trough delivery, and other issues. Among these are devices such … include things such as the sustained-release bimatoprost (Bimatoprost SR, Allergan) and iDose (Glaukos). “Each of those two systems have their limitations,” Dr. Bacharach said. With iGAPS, efficacy is great, but there are safety concerns …

Amgen

The Medicines Company (MDCO) CEO Mark Timney on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 10/30/2019

… so that ASCVD patients consistently reach their goal and avoid cardiovascular events. And second, underlying this first need is core patient adherence to LDL-C lowering therapy. Based on the exceptional data presented so far … on the flawless execution through the quarter. Interesting to hear Amgen’s management team commented last evening on inclisiran. Mark, wondering if you could comment would you or even Diane might be hearing from your industry …

GE Healthcare

The global sleep apnea devices market size is estimated to be worth USD 12.61 billion by 2025, expanding at a CAGR of 6.8% from 2019 to 2025 | PR Newswire | 10/22/2019

… GE Healthcare; Fisher & Paykel Healthcare Limited; Curative Medical Inc.; Cadwell Laboratories ResMed; Invacare Corporation; Braebon Medical Corporation; ImThera Medical Inc.; Phillips Respironics; Curative Medical Inc.; Nihon Kohden; and Compumedics Limited. Further key findings from the report suggest: • Therapeutic devices segment led the market in 2018, with a revenue of USD 5,302.1 million , due to high prevalence of OSA, increased treatment rate, patient adherence, and availability of technologically advanced products • Oral …

Merck & Co

World Endometriosis Drugs Market Report 2019-2023 - ResearchAndMarkets.com | Business Wire | 10/21/2019

… to reduce the cost burden on patients. The availability of patient assistance programs for high-cost branded drugs will increase patient adherence to such drugs medications, which is expected to have a positive impact on … Bayer AG Johnson & Johnson Services Inc. Mayne Pharma Group Ltd. Merck & Co. Inc. Pfizer Inc. Takeda Pharmaceutical Co. Ltd. Teva Pharmaceutical Industries Ltd. Also, the endometriosis drugs market analysis report includes information on upcoming trends …

AbbVie

World Endometriosis Drugs Market Report 2019-2023 - ResearchAndMarkets.com | Business Wire | 10/21/2019

AbbVie and Bayer are providing patient-assistance programs to reduce the cost burden on patients. The availability of patient assistance programs for high-cost branded drugs will increase patient adherence to such drugs medications, which is expected to have a positive impact on the overall market growth. Competitive Landscape With the presence of several major players, the global endometriosis drug market is moderately fragmented. The robust vendor analysis is designed …

McKesson

Patients Are the Key to Understanding Adherence | 10/11/2019

Friday, October 11, 2019 Patients Are the Key to Understanding Adherence Today’s guest post come from Heather Morel, Senior Vice President and General Manager of Access and Adherence at RxCrossroads by McKesson. Heather discusses how to overcome barriers to patient adherence. To learn more about RxCrossroads by McKesson’s patient support programs, download their free white paper: The Impact of Behavioral Coaching on Adherence . Read on for Heather’s insights. Patients Are …

Goldman Sachs

The Medicines Company (MDCO) CEO Mark Timney on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 10/30/2019

… Umer Raffat - Evercore Dae Gon - SVB Jessica Fye - JPMorgan Tazeen Ahmad - Bank of America Yasmeen Rahimi - Roth Capital Paul Choi - Goldman Sachs Chris Shibutani - Cowen Mayank Mamtani - B. Riley Akash Tewari - Wolfe Research Madhu Kumar … cardiovascular events. And second, underlying this first need is core patient adherence to LDL-C lowering therapy. Based on the exceptional data presented so far, we believe inclisiran is well positioned to address the significant …

Insmed Announces Closing of Public Offering of Common Stock | PR Newswire | 6/27/2019

… the acquisition or in‑license of additional compounds, product candidates, technology or businesses. Morgan Stanley & Co. LLC, SVB Leerink LLC and Goldman Sachs & Co. LLC acted as joint book-running managers for the offering. Credit Suisse … rates of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates; the Company’s inability to create an effective direct sales and marketing infrastructure or to partner with third parties that offer …

Morgan Stanley

Insmed Announces Closing of Public Offering of Common Stock | PR Newswire | 6/27/2019

… for other general corporate purposes, which may include the acquisition or in‑license of additional compounds, product candidates, technology or businesses. Morgan Stanley & Co. LLC, SVB Leerink LLC and Goldman Sachs & Co. LLC acted as joint … rates of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates; the Company’s inability to create an effective direct sales and marketing infrastructure or to partner with third parties that offer …

Insmed Announces Closing of Public Offering of Common Stock | Business & Finance | heraldchronicle.com | PR Newswire | 6/26/2019

… for other general corporate purposes, which may include the acquisition or in‑license of additional compounds, product candidates, technology or businesses. Morgan Stanley & Co. LLC, SVB Leerink LLC and Goldman Sachs & Co. LLC acted as joint … rates of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates; the Company’s inability to create an effective direct sales and marketing infrastructure or to partner with third parties that offer …

SVB Leerink

Insmed Announces Closing of Public Offering of Common Stock | PR Newswire | 6/27/2019

… purposes, which may include the acquisition or in‑license of additional compounds, product candidates, technology or businesses. Morgan Stanley & Co. LLC, SVB Leerink LLC and Goldman Sachs & Co. LLC acted as joint book-running managers for … rates of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates; the Company’s inability to create an effective direct sales and marketing infrastructure or to partner with third parties that offer …

Insmed Announces Closing of Public Offering of Common Stock | Business & Finance | heraldchronicle.com | PR Newswire | 6/26/2019

… purposes, which may include the acquisition or in‑license of additional compounds, product candidates, technology or businesses. Morgan Stanley & Co. LLC, SVB Leerink LLC and Goldman Sachs & Co. LLC acted as joint book-running managers for … rates of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates; the Company’s inability to create an effective direct sales and marketing infrastructure or to partner with third parties that offer …

Medical Center

ACC: Medtronic’s renal denervation study returns, showing drops in stubbornly high blood pressure | FierceBiotech | 3/29/2020

patient adherence for reducing blood pressure,” said study lead author Michael Böhm of the Saarland University Medical Center in Hamburg, Germany. The 24-hour wearable monitor also tracked lower blood pressure readings throughout the night and early mornings, when the effects of blood pressure medications are reduced and the risk is highest for adverse events, Böhm said. The international study enrolled 331 total patients with high blood pressure, with half …

Secret shoppers find telemedicine dispenses birth control appropriately | MobiHealthNews | 10/3/2019

… for the ability to ingest the medication. “Telecontraception vendors could increase the quality of their services by improving screening for patient adherence to the regimen of ingesting a pill daily and for rare contraindications to … Harvard Medical School and a hospitalist at Beth Israel Deaconess Medical Center, said in a statement. THE LARGER TREND More and more companies are offering contraceptives through a virtual medicine platform. Pill Club , a company …

Harvard Medical School

Epigenomics AG Reports on New Micro-Simulation Study Results Published in Cancer Medicine Indicating That Epi proColon® Provides Clinically Meaningful Reductions in Incidence and Mortality of Colorectal Cancer | BioSpace | 12/2/2019

… and mortality of CRC comparable to those of USPSTF currently recommended methods. The micro-simulation model, developed and validated at Harvard Medical School, evaluated the impact of adherence rates, testing intervals and clinical performance of … strategies, the results of this micro-simulation model demonstrate that patient adherence and prescribed screening intervals heavily influence the long-term clinical effectiveness for all CRC screening strategies,” said Daniel Sussman, MD, University of Miami …

Epigenomics AG Reports on New Micro-Simulation Study Results Published in Cancer Medicine Indicating That Epi proColon® Provides Clinically Meaningful Reductions in Incidence and Mortality of Colorectal Cancer | 12/2/2019

… and mortality of CRC comparable to those of USPSTF currently recommended methods. The micro-simulation model, developed and validated at Harvard Medical School, evaluated the impact of adherence rates, testing intervals and clinical performance of … strategies, the results of this micro-simulation model demonstrate that patient adherence and prescribed screening intervals heavily influence the long-term clinical effectiveness for all CRC screening strategies,” said Daniel Sussman, MD, University of Miami …

Mayo Clinic

Biofourmis Announces Acquisition of Biovotion AG, Completing Biovitals® Platform to Deliver Precise Interventions at the Right Time to Manage Patients with Complex Chronic Conditions | PR Newswire | 11/18/2019

… than 80 current and previous partners—including large global pharmaceutical companies and contract research organizations (CROs), healthcare providers such as Mayo Clinic and the University Hospital of Basel , and technology partners such as IBM Research … 80% adherence rates among patients and study participants. The high patient adherence rate and accurate data collection of numerous clinical and non-clinical parameters are two of the primary reasons Biofourmis commonly uses the device …

Twice-yearly inclisiran cuts LDL in ASCVD patients | 11/16/2019

… 56% from month 3 to 18 ( P .0001), R. Scott Wright, MD, professor of medicine and consultant in cardiology at Mayo Clinic in Rochester, said during a presentation at Sessions. “Inclisiran potentially offers a novel … said. Watson acknowledged that the impact of infrequent dosing on patient adherence remains unclear. “I would love to say that most of my patients come to see me twice a year, but they don’t. I …

Banner Health

Current Health Names Former Skyscanner Executive Richard Lennox as Chief Operating Officer | Business Wire | 7/16/2019

… thriving tech sector.” Current Health is partnering with six of the U.S.’s largest health systems, including Mount Sinai and Banner Health, and several NHS Trusts in the U.K. to help reduce hospital readmissions and … with the patient in mind. It has over a 90% patient adherence rate, and they report feeling safer and more secure wearing it. CE-marked in the U.K. and FDA-cleared for both in-hospital …

Current Health Receives FDA Clearance for its Remote Patient Monitoring Solution for In-Home Care, Demonstrates Reduced Hospital Readmissions | Business & Finance | manchestertimes.com | Business Wire | 4/24/2019

… patient adherence. “Real-time, at-home monitoring of vitals allows our team to proactively act on early signs of health decline, preventing avoidable hospitalizations,” said Dr. Neta Faynboym MD, CPE Executive Director, Innovation: Medicare Advantage/Affordability, at Banner Health. Designed specifically with the patient in mind, Current passively measures a patient’s vital signs in real time with its upper-arm wearable. Developed using one of the world’s largest physiological data …

University Hospital

Can the bot-to-patient relationship improve patient engagement? | MobiHealthNews | 7/4/2019

University Hospital Gui de Chauliac and European Hospital Georges Pompidou in Paris. The results are particularly encouraging in terms of treatment effectiveness. Improved patient adherence The trial meant that 4,737 patients with breast cancer were enrolled and observed over one year to evaluate their functional and emotional interactions with the chatbot, and quantify their adherence using the assistance in disease follow-up. On average 132,970 messages were exchanged per month …

Hacettepe University Oncology Hospital Introduces Omnicell i.v.STATION ONCO Robots to Chemotherapy | PR Newswire | 12/6/2017

… technology to support streamlined pharmacy operations and patient safety, helping to maintain its ranking as one of Turkey’s most prestigious university hospitals. In Hacettepe’s outpatient chemotherapy unit, the i.v.STATION ONCO promotes optimal patient safety through … North America and the United Kingdom , are designed to improve patient adherence to prescriptions, helping to reduce costly hospital readmissions. Recent Omnicell acquisitions, including Ateb, add distinct capabilities, particularly in central pharmacy, IV robotics, and …

Children's Hospital

Texas Children’s Hospital Implements Omnicell Performance Center and Upgrades Medication Management | PR Newswire | 11/8/2017

MOUNTAIN VIEW, Calif. Omnicell, Inc. (NASDAQ: OMCL ) today announced that Texas Children’s Hospital , located in Houston, Texas , selected Omnicell ® Performance Center ™ to improve pharmacy operations and optimize medication management across its health system. Texas Children’s … North America and the United Kingdom, are designed to improve patient adherence to prescriptions, helping to reduce costly hospital readmissions. Recent Omnicell acquisitions, including Ateb, add distinct capabilities, particularly in central pharmacy, IV robotics, and …

Texas Children’s Hospital Implements Omnicell Performance Center and Upgrades Medication Management Automation | PR Newswire | 11/8/2017

Texas Children’s Hospital Implements Omnicell Performance Center and Upgrades Medication Management Automation Combination of Professional Pharmacy Services, Hardware, and Software Helps Create Consistency and Improve Performance Across Health System News provided by 08:00 ET Share … North America and the United Kingdom, are designed to improve patient adherence to prescriptions, helping to reduce costly hospital readmissions. Recent Omnicell acquisitions, including Ateb, add distinct capabilities, particularly in central pharmacy, IV robotics, and …

Health Net

Edited Transcript of HSM.TO earnings conference call or presentation 12-Mar-20 9:00pm GMT | Yahoo News | 3/29/2020

… Institute at the KITE Research Institute, the research arm of the Toronto Rehabilitation Institute and a member of the University Health Network or UHN. Let me provide you with a quick agenda for today’s call … conferences and events. We are continuing to gather data on patient adherence and treatment outcomes as part of our strategy to generate the requisite support, demonstrating the quality of life and health economic benefits of …

Highmark Health’s VITAL Innovation Program Validates Effective Drug-Free Treatment for Panic Attacks | PR Newswire | 11/28/2017

… reduced by 50%, ER costs by 64%, and medication costs by 53%(1) PITTSBURGH and DANVILLE, Calif. Highmark Health, Allegheny Health Network and Palo Alto Health Sciences, manufacturer of Freespira, today announced the results of … promising to see high therapist and patient satisfaction and 85% patient adherence 1 , confirming that using Freespira as a first line treatment for panic disorder and panic attacks makes good sense clinically and financially.” About …

Will Lewis

Insmed Receives Positive CHMP Opinion for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Non-CF Patients with Limited Treatment Options | PR Newswire | 7/24/2020

… the first therapy in both the European Union and the United States for patients with this chronic, debilitating condition,” said Will Lewis , Chairman and Chief Executive Officer of Insmed. “We look forward to potentially bringing … rates of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates; the Company’s inability to create an effective direct sales and marketing infrastructure or to partner with third parties that offer …

Insmed Appoints Carol A. Schafer to its Board of Directors | PR Newswire | 4/2/2020

… as a Managing Partner at Hyphen Advisors, LLC. “We are thrilled to welcome Carol to our Board of Directors,” said Will Lewis , Chairman and CEO of Insmed. “In addition to her strong financial acumen, Carol … rates of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates; the Company’s inability to create an effective direct sales and marketing infrastructure or to partner with third parties that offer …

Kevin Conroy

Exact Sciences Highlights The Opportunity To Seek Screening With Cologuard® Through Telehealth | PR Newswire | 4/2/2020

… we are letting people know they can request Cologuard online from a health care provider, without an office visit,” said Kevin Conroy , Exact Sciences chairman and CEO. “While Americans are at home trying to prevent … future operating results, anticipated results of our sales, marketing and patient adherence efforts, expectations concerning payer reimbursement and regulatory matters, the anticipated results of our product development efforts and the anticipated benefits of our combination …

Exact Sciences Highlights The Opportunity To Seek Screening With Cologuard® Through Telehealth | Markets Insider | Business Insider | 4/2/2020

… we are letting people know they can request Cologuard online from a health care provider, without an office visit,” said Kevin Conroy , Exact Sciences chairman and CEO. “While Americans are at home trying to prevent … future operating results, anticipated results of our sales, marketing and patient adherence efforts, expectations concerning payer reimbursement and regulatory matters, the anticipated results of our product development efforts and the anticipated benefits of our combination …

Vas Narasimhan

Novartis to acquire The Medicines Company for USD 9.7 bn, adding inclisiran, a potentially transformational investigational cholesterol-lowering therapy to address leading global cause of death | Globe Newswire | 11/24/2019

… thirties in the near term and mid-to-high thirties in the medium term Basel, November 24, 2019 — Novartis CEO Vas Narasimhan said: “ We are excited about entering into an agreement to acquire The Medicines … to their healthcare professionals and will likely contribute to improved patient adherence and sustained, lower LDL-C levels 2,3,4 . The Medicines Company expects to file regulatory submissions in the U.S. in the fourth quarter of …

Novartis to acquire The Medicines Company for USD 9.7 bn, adding inclisiran, a potentially transformational investigational cholesterol-lowering therapy to address leading global cause of death – Company Announcement - FT.com | Financial Times | 11/24/2019

… thirties in the near term and mid-to-high thirties in the medium term Basel, November 24, 2019 — Novartis CEO Vas Narasimhan said: “ We are excited about entering into an agreement to acquire The Medicines … to their healthcare professionals and will likely contribute to improved patient adherence and sustained, lower LDL-C levels 2,3,4 . The Medicines Company expects to file regulatory submissions in the U.S. in the fourth quarter of …

Mark Timney

The Medicines Company (MDCO) CEO Mark Timney on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 10/30/2019

… Q3 2019 Earnings Conference Call October 30, 2019 8:30 AM ET Company Participants Krishna Gorti - Vice President of Investor Relations Mark Timney - Chief Executive Officer Christopher Visioli - Chief Financial Officer Peter Wijngaard - Chief Development Officer … cardiovascular events. And second, underlying this first need is core patient adherence to LDL-C lowering therapy. Based on the exceptional data presented so far, we believe inclisiran is well positioned to address the significant …

Medicines Co (MDCO) Q3 2019 Earnings Call Transcript | The Motley Fool | 10/30/2019

… and welcome to The Medicines Company’s Third Quarter 2019 Earnings Conference Call. I’m joined today by our Chief Executive Officer, Mark Timney; our Chief Financial Officer, Christopher Visioli; our Chief Development Officer, Peter Wijngaard. Earlier … cardiovascular events. And second underlying this first need is poor patient adherence to LDL-C lowering therapy. Based on the exceptional data presented so far, we believe inclisiran is well positioned to address the significant …

Umer Raffat

The Medicines Company (MDCO) CEO Mark Timney on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 10/30/2019

… Christopher Visioli - Chief Financial Officer Peter Wijngaard - Chief Development Officer Christopher Visioli - Chief Development Officer, Peter Wijngaard Conference Call Participants Umer Raffat - Evercore Dae Gon - SVB Jessica Fye - JPMorgan Tazeen Ahmad - Bank of America Yasmeen … cardiovascular events. And second, underlying this first need is core patient adherence to LDL-C lowering therapy. Based on the exceptional data presented so far, we believe inclisiran is well positioned to address the significant …

Medicines Co (MDCO) Q3 2019 Earnings Call Transcript | The Motley Fool | 10/30/2019

… so that ASCVD patients consistently reach their goal, and avoid cardiovascular events. And second underlying this first need is poor patient adherence to LDL-C lowering therapy. Based on the exceptional data presented so far … Operator Instructions] Our first question comes from the line of Umer Raffat with Evercore. Please proceed your question. Umer Raffat – Evercore ISI – Analyst Hi. Thanks so much for taking my questions. Mark, can you speak …

Kamal Anand

Fixing Patient Access: Asparia Announces First Chatbot Embedded in Electronic Health Records | Business Wire | 10/8/2019

… Kamal Anand, CEO & Co-Founder, Asparia. “We give a voice to those care needs, whether it’s keeping appointments or getting preventive check-ups. As a result, health systems can manage patient adherence with automated technology.” Today, staff time is wasted on repetitive and ineffective administrative tasks trying to get patients to keep appointments and re-checks. Asparia automates these tasks to improve consistency, adherence and reduces the staff’s administrative burden …

Fixing Patient Access: Asparia Announces First Chatbot Embedded in Electronic Health Records | BioSpace | 10/8/2019

… Kamal Anand, CEO & Co-Founder, Asparia. “We give a voice to those care needs, whether it’s keeping appointments or getting preventive check-ups. As a result, health systems can manage patient adherence with automated technology.” Today, staff time is wasted on repetitive and ineffective administrative tasks trying to get patients to keep appointments and re-checks. Asparia automates these tasks to improve consistency, adherence and reduces the staff’s administrative burden …

Kal Patel

BrightInsight Raises $25 Million to Enhance its Regulated Digital Health Platform and Accelerate Global Commercialization | PR Newswire | 9/5/2019

… BrightInsight Platform has become the leading global regulated digital health platform for the world’s top biopharma and medtech companies,” said Kal Patel , MD, CEO and Co-Founder, BrightInsight. “Our investors have strong pedigrees in healthcare … and actionable insights. It also enables our customers to increase patient adherence and engagement. Having achieved the upmost privacy, security, regulatory and quality certifications, BrightInsight was selected as Novo Nordisk’s global digital health partner to …

BrightInsight, a Flex Company, Receives 2018 Google Cloud Partner of the Year Award for Healthcare and Life Sciences | Business Wire | 4/10/2019

… are honored to be recognized by Google Cloud for the transformative work we are doing with the BrightInsight Platform,” said Kal Patel, MD, President, BrightInsight. “Our platform is built under a Quality Management System to … data and actionable insights to enable customers to drive increased patient adherence and engagement. The BrightInsight™ Platform uses software and services to capture, transmit and analyze data from CE-marked and FDA-regulated medical devices …

William H. Lewis

Insmed Announces Closing of Public Offering of Common Stock | PR Newswire | 6/27/2019

… up to an additional 1,042,307 shares of common stock from Insmed and up to 400,000 shares of common stock from William H. Lewis , the Company’s Chairman and Chief Executive Officer at a public offering price … rates of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates; the Company’s inability to create an effective direct sales and marketing infrastructure or to partner with third parties that offer …

Insmed Announces Closing of Public Offering of Common Stock | Business & Finance | heraldchronicle.com | PR Newswire | 6/26/2019

… up to an additional 1,042,307 shares of common stock from Insmed and up to 400,000 shares of common stock from William H. Lewis, the Company’s Chairman and Chief Executive Officer at a public offering price … rates of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates; the Company’s inability to create an effective direct sales and marketing infrastructure or to partner with third parties that offer …

William Lewis

Insmed Announces Closing of Public Offering of Common Stock | PR Newswire | 6/27/2019

… the Company’s estimates of the size of the potential markets for ARIKAYCE or in data the Company has used to identify physicians, expected rates of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates; the Company’s inability to create an effective direct sales and marketing infrastructure or to partner with third parties that offer such an infrastructure for distribution of ARIKAYCE; failure to obtain regulatory approval …

Insmed Announces Closing of Public Offering of Common Stock | Business & Finance | heraldchronicle.com | PR Newswire | 6/26/2019

… the Company’s estimates of the size of the potential markets for ARIKAYCE or in data the Company has used to identify physicians, expected rates of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates; the Company’s inability to create an effective direct sales and marketing infrastructure or to partner with third parties that offer such an infrastructure for distribution of ARIKAYCE; failure to obtain regulatory approval …

Omri Shor

AmerisourceBergen’s Lash Group teams up with Medisafe to address patient adherence | MedCity News | 4/29/2019

Health IT , Pharma AmerisourceBergen’s Lash Group teams up with Medisafe to address patient adherence Through their alliance, Medisafe will deliver real-time interventions to help patients stay adherent and will alert Lash Group’s clinicians when … to better engage with patients. In a statement, Medisafe CEO Omri Shor commented: We are excited to move upstream in the patient journey making it easier for new patients to get started on therapy. And …

Lash Group and Medisafe Form Strategic Collaboration to Advance Patient Adherence by Deploying Mobile Engagement Before the First Fill | Malvern Daily Record | 4/29/2019

… of AmerisourceBergen, and Medisafe, a leading medication management platform, today announced that, together, they will provide an end-to-end patient adherence solution that combines a top-rated mobile platform within Lash Group’s current hub … trained clinician is never more than a tap away,” said Omri Shor, CEO of Medisafe. “Our strategic collaboration will improve the well-being of patients with severe illness and complex medication regimens at scale by …